Erdafitinib is a pan-FGFR inhibitor with a quinoxaline core which was granted accelerated approval by the FDA for the first-line treatment of urinary bladder tumors with FGFR2/3 mutant or FGFR2/3 fusion and the second-line treatment of metastatic or unresectable urothelial carcinoma. Here, FGFR2 is linked to urinary bladder neoplasm.